Cryo-EM structures of human OAT1 reveal drug binding and inhibition mechanisms

Hyung-Min Jeon1, Jisung Eun1, Kelly H Kim2

  • 1Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.

PubMed

Insights

Structural insights into human organic anion transporter 1 (hOAT1) reveal how substrates like olmesartan and inhibitors like probenecid bind. This clarifies transport mechanisms and potential drug interactions.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Organic anion transporter 1 (OAT1) is crucial for drug metabolism and disposition.
  • Understanding OAT1's structure is key to predicting drug-drug interactions.

Purpose of the Study:

  • Elucidate the structural basis of substrate and inhibitor transport by human OAT1 (hOAT1).
  • Investigate the role of specific residues and ions in hOAT1 function.

Main Methods:

  • Determined four cryogenic electron microscopy (cryo-EM) structures of hOAT1.
  • Analyzed apo, substrate-bound (olmesartan), and inhibitor-bound (probenecid) forms.

Main Results:

  • Identified Ser203's role in chloride coordination and olmesartan transport.
  • Showed inhibitors block substrate entry/exit, increasing retention.
  • Revealed structural differences between substrate and inhibitor binding.

Conclusions:

  • OAT1 structure provides insights into substrate recognition and inhibitor mechanisms.
  • Findings aid in developing drugs with fewer interactions and better disposition.
  • Chloride ions play a key role in OAT1-mediated transport.

Related Concept Videos

Cryo-electron Microscopy01:28

Cryo-electron Microscopy

Conventional electron microscopy (EM) involves dehydration, fixation, and staining of biological samples, which distorts the native state of biological molecules and results in several artifacts. Also, the high-energy electron beam damages the sample and makes it difficult to obtain high-resolution images. These issues can be addressed using cryo-EM, which uses frozen samples and gentler electron beams. The technique was developed by Jacques Dubochet, Joachim Frank, and Richard Henderson, for...
3.6K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
931
Gene Families01:57

Gene Families

Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
9.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
249